Neurocrine Biosciences (NBIX) Retained Earnings (2010 - 2026)
Neurocrine Biosciences (NBIX) posted quarterly Retained Earnings of $724.0 million for Q2 2026, up 756.8% year-over-year from $84.5 million in Q2 2025, and up 22.8% on a QoQ basis from $589.6 million in Q1 2026.
Neurocrine Biosciences (NBIX) Retained Earnings (2010 - 2026) Analysis & Trends
Neurocrine Biosciences has reported Retained Earnings for 17 years, with the latest figure at $724.0 million in Q2 2026.
- Retained Earnings for Q2 2026 came in at $724.0 million, up 756.8% year-over-year; the trailing twelve-month figure through Jun 2026 was $724.0 million (up 756.8% YoY), and the FY2025 annual result was $447.7 million, up 1433.22% from the prior year.
- Retained Earnings improved to $724.0 million in Q2 2026, from $589.6 million in the prior quarter.
- Over five years, Retained Earnings peaked at $724.0 million in Q2 2026 and troughed at -$564.3 million in Q2 2022.
- A 5-year average of -$69.5 million and a median of -$81.2 million in 2024 frame the typical range for Retained Earnings.
- The widest annual swing landed in 2023, when Retained Earnings rose 11.69%; it then soared 6451.11% in 2026.
- A 5-year view of Retained Earnings shows it stood at -$406.8 million in 2022, then jumped by 61.38% to -$157.1 million in 2023, then jumped by 118.59% to $29.2 million in 2024, then soared by 1433.22% to $447.7 million in 2025, then soared by 61.72% to $724.0 million in 2026.
- Per Business Quant data, the three most recent Retained Earnings figures were $724.0 million in Q2 2026, $589.6 million in Q1 2026, and $447.7 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.76 Bn | 42.79 Bn | - | 37.15 Bn |
| 2 | Teva Pharmaceutical Industries | 43.38 Bn | 39.73 Bn | 2.15 Bn | 28.26 Bn |
| 3 | Zoetis | 31.61 Bn | 29.93 Bn | 1.05 Bn | 14.65 Bn |
| 4 | Takeda Pharmaceutical | 28.64 Bn | 22.84 Bn | 5.10 Bn | 4.18 Bn |
| 5 | United Therapeutics | 22.20 Bn | 19.54 Bn | 683.80 Mn | 9.16 Bn |
| 6 | Viatris | 18.82 Bn | 17.93 Bn | 1.46 Bn | 18.56 Bn |
| 7 | Neurocrine Biosciences | 15.67 Bn | 15.28 Bn | 935.80 Mn | 724.00 Mn |
| 8 | Elanco Animal Health | 12.11 Bn | 11.58 Bn | 798.00 Mn | 8.88 Bn |
| 9 | Dr Reddys Laboratories | 10.10 Bn | 9.94 Bn | - | 3.75 Bn |
| 10 | Alkermes | 8.21 Bn | 7.55 Bn | 397.90 Mn | -800.77 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 724.00 Mn |
| Mar 31, 2026 | 589.60 Mn |
| Dec 31, 2025 | 447.70 Mn |
| Sep 30, 2025 | 13.20 Mn |
| Jun 30, 2025 | 12.50 Mn |
| Mar 31, 2025 | 9.00 Mn |
| Dec 31, 2024 | 5.80 Mn |
| Sep 30, 2024 | 14.50 Mn |
| Jun 30, 2024 | -48.70 Mn |
| Mar 31, 2024 | 3.30 Mn |
| Dec 31, 2023 | -157.10 Mn |
| Sep 30, 2023 | -1.70 Mn |
| Jun 30, 2023 | -1.10 Mn |
| Mar 31, 2023 | -483.40 Mn |
| Dec 31, 2022 | -7.90 Mn |
| Sep 30, 2022 | -495.80 Mn |
| Jun 30, 2022 | -564.30 Mn |
| Mar 31, 2022 | -547.40 Mn |
| Dec 31, 2021 | -1.70 Mn |
| Sep 30, 2021 | 400,000.00 |